CONTRACT FOR CARE · RIGHTS, CONSENT & GOVERNMENT POWER

Our Legal Case

A patient’s need for medicine should not become the pressure used to obtain a criminal admission. Examine compulsory disclosures, penalties for silence, coerced rights waivers, and the circumstances behind the signature.

Use the original agreement and policy sources for this record to identify the exact clause, its legal source, and the stated consequence. Preserve those facts before reaching a conclusion about a particular provider or condition.

Apply the constitutional and consent review to this record
  1. Government responsibility: Which law, binding rule, agency instruction, or public-provider policy requires the particular disclosure or consequence? Separate it from provider-added terms.
  2. Potential criminal admission: Identify the exact spoken answer, written history, certification, or explanation and the real criminal risk it creates.
  3. Penalty for silence: Record what happens if the patient invokes the privilege or refuses a rights waiver, including denial, discharge, or interruption of treatment.
  4. Consent and pressure: Preserve the circumstances of signing, severity of pain, accessible alternatives, and whether the patient could honestly accept the prospective obligations.
  5. Criminal-use protection: Identify legally sufficient immunity and limits on use of both the answer and evidence derived from it. A privacy assurance is a separate protection.

Read the precedents, evidence framework, clause review, and remedies and reform demands. The work develops a proposed constitutional challenge; applying it to a particular condition requires its facts and legal authority.

MASSACHUSETTS · CONTRACT FOR CARE

Norwood Comprehensive Pain Management — Opioid Consent

Public institutional form — current signed use unconfirmed

Document/version: Footer appears PC6/17/2014 in retrieved scan; interpretation not confirmed. 3 PDF pages.

Three-page scan linked by current patient-forms page. Printed footer is not independently confirmed as an effective date. Posted Practice Policies page says Coming Soon. No office current-use confirmation.

Requirements and documented consequences

This table paraphrases source-located terms. Use the original PDF for exact complete wording. PDF page numbers count from the first page, including packet covers.

Source locationRequirement summaryClassificationStated consequence
p.1, §1Use prescribed dose; dose changes risk overdose/withdrawal.Required subject; method variesNo distinct penalty specified here.
p.1, §§2–3Recognize/report side effects; notify other care, emergency visits or pregnancy.Required subject; method variesNo distinct penalty specified here.
p.1, §4No sharing or sale.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.1, §5Disclose all medicines and interactions.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.1, §6Dose-adjustment visits; stable-dose clinic review at least six-monthly.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.1, §7No mailing; inability to collect monthly requires local prescribing arrangement.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.1, §8Hoarding, outside analgesics, dose changes or lost prescriptions may end relationship.Clinic term beyond §18A baselinePossible relationship termination.
p.2, §9Communicate pain, function and side effects.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.2, §§10–11Prohibits listed illicit substances and alcohol with opioids.Clinic term beyond §18A baselinePossible discontinuation/dismissal.
p.2, §12(a,b,d,f,h,i,j)Monthly same-pharmacy refills; advance scheduling; no urgent/walk-in/vacation exceptions.Clinic term beyond §18A baselineNo immediate refill appointment.
p.2, §12(c)Safeguard medicines; theft police report; loss may lead to nonreplacement/taper.Clinic term beyond §18A baselinePossible nonreplacement or discontinuation.
p.2, §12(e)Massachusetts-only pharmacy fills, including out-of-state residents.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.2, §12(g)Bring original medication bottles at every visit.Clinic term beyond §18A baselineNo distinct penalty specified here.
pp.2–3, §§13–15Distinguishes dependence/addiction; taper, specialist/recovery referral when indicated.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.3, §16Enough medication between visits; limited weekend/holiday contingency.Clinic term beyond §18A baselineNo distinct penalty specified here.
p.3, §17Random testing; refusal or specified results may end opioids or relationship.Clinic term beyond §18A baselineSafe discontinuation/dismissal stated.
p.3, §§18–19Allows disclosures to family/legal authorities and clinician-requested conference.Legal review requiredScope requires review.
p.3, §20Noncompliance may change plan, taper opioids or dismiss.Clinic term beyond §18A baselinePossible taper or clinic discharge.

Comparison with Massachusetts authority

M.G.L. c.94C §18A(b) requires an agreement addressing benefits and abuse/misuse risks when a registered practitioner recommends ER/LA opioids during long-term pain management. Record placement follows that subsection. Narrow hydrocodone professional rules, written informed-consent duties, and MassHealth coverage criteria are separate layers.

§18A does not itself prescribe these exact deadlines, charges, disclosure terms or dismissal mechanics. 243CMR2.07(25) addresses screening, counts and safe storage for a narrow formulation and patient-specific risk; §2.07(26) separately governs informed consent. A required subject does not make every implementation mandatory.

DIA’s October 2024 chronic-pain guideline addresses agreements, bilateral responsibilities and continuity within the injured-worker context. DIA says its guidelines are not mandates. Coverage terms must be mapped to the actual payer/program.

Connected offices

Current copy and practice response

Patients can submit the version presented to them. Practices can supply a current blank form, dates, applicable offices/groups, exceptions and corrections. Historical versions remain linked. No motive or legality finding is made. Privacy, termination, pregnancy-testing and partial-fill interpretations remain open for owner/legal review.

Research: October 12, 2026. Methodology. Factual comparison published with stated interpretation limits.